Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Avalo Therapeutics (AVTX)
NASDAQ:AVTX
RESEARCH TOOLSreports
Holding AVTX?
Track your performance easily
AVTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.95 - $34.46
Previous Close$13.25
Volume45.97K
Average Volume (3M)28.07K
Market Cap
$131.69M
Enterprise Value$44.29M
Total Cash (Recent Filing)$93.43M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.08
Next Earnings
Mar 27, 2025EPS Estimate
-$1.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-168.23
Shares Outstanding10,393,954
10 Day Avg. Volume35,262
30 Day Avg. Volume28,071
Standard Deviation0.60
R-Squared0.00808
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)-10.12
Price to Sales (P/S)171.43
Price to Cash Flow (P/CF)-2.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue54.89
Enterprise Value/Gross Profit69.21
Enterprise Value/Ebitda0.54
Forecast
1Y Price Target
$35.00Price Target Upside176.24% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Avalo Therapeutics News
Bulls Say, Bears Say
Bulls Say
Financial StabilityManagement expects the company has a cash runway at least into 2027.
Market GrowthThe targeted diagnosed and treated HS population is projected to grow to an over $9.5 billion market by 2035.
Product PotentialAVTX-009 has high potency and convenient dosing that provides the potential to be a best-in-class product for the treatment of hidradenitis suppurativa (HS) and other immune-inflammatory diseases.
Bears Say
EarningsThe company's earnings per share fell short of analyst expectations by a wide margin, highlighting potential challenges in managing costs or generating revenue.
Financial PerformanceAvalo reported a significantly larger loss per share than analysts estimated, indicating weaker than expected financial performance.
Investor ConfidenceA larger than anticipated decline in earnings per share may erode investor confidence in Avalo's financial management and future profitability.
---
Ownership Overview
5.60%
Insiders
0.19% Mutual Funds
<0.01% Other Institutional Investors
94.11% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
AVTX FAQ
What was Avalo Therapeutics’s price range in the past 12 months?
Avalo Therapeutics lowest stock price was $3.95 and its highest was $34.46 in the past 12 months.
What is Avalo Therapeutics’s market cap?
Currently, no data Available
When is Avalo Therapeutics’s upcoming earnings report date?
Avalo Therapeutics’s upcoming earnings report date is Mar 27, 2025 which is in 135 days.
How were Avalo Therapeutics’s earnings last quarter?
Avalo Therapeutics released its earnings results on Nov 07, 2024. The company reported -$2.83 earnings per share for the quarter, missing the consensus estimate of -$1.19 by -$1.64.
Is Avalo Therapeutics overvalued?
According to Wall Street analysts Avalo Therapeutics’s price is currently Undervalued.
Does Avalo Therapeutics pay dividends?
Avalo Therapeutics does not currently pay dividends.
What is Avalo Therapeutics’s EPS estimate?
Avalo Therapeutics’s EPS estimate is -$1.12.
How many shares outstanding does Avalo Therapeutics have?
Avalo Therapeutics has 10,393,954 shares outstanding.
What happened to Avalo Therapeutics’s price movement after its last earnings report?
Avalo Therapeutics reported an EPS of -$2.83 in its last earnings report, missing expectations of -$1.19. Following the earnings report the stock price went down -3.657%.
Which hedge fund is a major shareholder of Avalo Therapeutics?
Currently, no hedge funds are holding shares in AVTX
---
Avalo Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$35.00 (176.24% Upside)
$35.00 (176.24% Upside)
Blogger Sentiment
Bullish
AVTX Sentiment 100%
Sector Average 73%
Sector Average 73%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 3.5%
Last 30 Days ▼ 3.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-38.92%
12-Months-Change
Fundamentals
Return on Equity
-42.52%
Trailing 12-Months
Asset Growth
236.37%
Trailing 12-Months
Company Description
Avalo Therapeutics
Cerecor, Inc. is a clinical stage biopharmaceutical company focuses in medical development. It involves in the discovery, manufacture and commercialization of prescription for neurological and psychiatric disorders. It products include CERC-301, CERC-501, CERC-611, and CERC-406. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher and Solomon H. Snyder on January 31, 2011 and is headquartered in Baltimore, MD.
---
AVTX Stock 12 Month Forecast
Average Price Target
$35.00
▲(176.24% Upside)
Technical Analysis
Eloxx Pharmaceuticals
―
EyePoint Pharmaceuticals
―
Fate Therapeutics
―
Karyopharm Therapeutics
―
Best Analysts Covering AVTX
1 Year
1 Year Success Rate
6/18 ratings generated profit
1 Year Average Return
-27.57%
reiterated a buy rating 5 days ago
Copying Leland Gershell's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -27.57% per trade.
---